A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
Crossref DOI link: https://doi.org/10.1007/s00240-017-0998-6
Published Online: 2017-07-17
Published Print: 2018-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Milliner, Dawn
Hoppe, Bernd
Groothoff, Jaap
License valid from 2017-07-17